Association of British Clinical Diabetologists

Exenatide QW Nationwide Audit

 
Home Live ABCD nationwide audits of new therapies All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Exenatide (Exendin-4) is the synthetic version of a salivary protein found in the Gila monster (shown above). It has approximately 50% identity with human GLP-1, it binds to known human GLP-1 receptors on beta cells in vitro, and is resistant to DPP-IV inactivation
 

Above: Gradual dissolution of the microspheres provides a steady release of exenatide  – click to enlarge
 

Above: At 30 weeks exenatide QW significantly improved HbA1c reductions compared to twice daily exenatide - click to enlarge
 

Above: The most common adverse events with exenatide QW were nausea, diarrhoea, injection-site pruritus, and vomiting. Nausea and vomiting occurred less frequently with exenatide QW compared to the twice daily preparation - click to enlarge
 

Above: Compared to the weight gain associated with use of insulin glargine, exenatide QW was associated with weight loss. But to what extent will this be reflected in real clinical use? - click to enlarge

ABCD nationwide exenatide QW audit on N3

Papers, abstracts, presentations, posters and webcasts emanating from the audit

 

Abstracts
ADA New Orleans, 2016 – Robert M. Gifford, Jalini Joharatnam, Ken Darzy, Ahmed Helmy, Edward McKeever, Ursula Brennon, Roy Harper, Keith Sands, Dennis Barnes, Robert E. Ryder, Karen A. Adamson. Change in HbA1c, Weight, and Blood Pressure in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Once Weekly (QW) Audit. Diabetes 2016 Jul; 65 (Supplement 1): 1036-P

 

Posters
ADA June 2016, Exenatide QW

    Register for the exenatide qw audit: UK

Register for the exenatide qw audit: Northern Ireland and non-UK

Register simulateously for both exenatide qw and dapagliflozin audits

Access the N3 on-line tool
(UK: you need to be on N3)

Access the worldwide on-line tool
(Northern Ireland and non-UK)

Exenatide QW audit objectives

Order preprinted data entry forms

Download first visit data entry form

Download follow up visit data entry form

Nationwide exenatide audit

Nationwide liraglutide audit

Further information- contact us

Main ABCD homepage

     

The ABCD nationwide exanatide QW audit is an independent audit supported by an unrestricted grant from Astra Zeneca

Working to support high quality diabetes care in the UK